natgillin/translations-raw huggingface dataset:
In 2.2% of patients taking ticagrelor and by 0.6% taking clopidogrel investigators considered the dyspnoea causally related to treatment in the PLATO study and few were serious (0.14% ticagrelor; 0.02% clopidogrel), (see section 4.4).
V študiji PLATO so raziskovalci dispnejo ocenili za vzročno povezano z uporabo zdravila pri 2,2 % bolnikov, ki so prejemali tikagrelor, in 0,6 % tistih, ki so prejemali klopidogrel in malo je bilo resnih (tikagrelor 0,14 %, klopidogrel 0,02 %) (glejte poglavje 4.4).
Patients should be advised to inform physicians and dentists that they are taking Possia before any surgery is scheduled and before any new medicinal product is taken.
Bolnikom je treba naročiti, da morajo pred načrtovanjem kakršnekoli operacije in preden vzamejo katerokoli novo zdravilo, zdravniku ali zobozdravniku povedati, da jemljejo zdravilo Possia.
• PVC-PVDC/Al transparent calendar blister (with sun/moon symbols) of 14 tablets; cartons of 14 tablets (1 blister), 56 tablets (4 blisters), and 168 tablets (12 blisters).
• Prosojen koledarski pretisni omot (s simboloma sonce/mesec) iz PVC-PVDC/Al s 14 tabletami; škatle s 14 tabletami (1 pretisni omot), 56 tabletami (4 pretisni omoti) in 168 tabletami (12 pretisnih omotov).
• rifampicin (an antibiotic), phenytoin, carbamazepine and phenobarbital (used to control seizures), dexamethasone (used to treat inflammatory and auto immune conditions), digoxin (used to treat heart failure), cyclosporin (used to lessen your body's defenses), quinidine and diltiazem (used to treat abnormal heart rhythms), beta blockers and verapamil (used to treat high
• rifampicin (antibiotik), fenitoin, karbamazepin in fenobarbital (uporabljajo se za obvladovanje napadov krčev), deksametazon (uporablja se za zdravljenje vnetnih in avtoimunskih bolezni), digoksin (uporablja se za zdravljenje srčnega popuščanja), ciklosporin (uporablja se za zmanjševanje telesne obrambe), kinidin in diltiazem (uporabljata se za zdravljenje motenj srčnega ritma), zaviralce adrenergičnih receptorjev beta in verapamil (uporabljajo se za zdravljenje visokega krvnega tlaka).
Other clinically meaningful adverse reactions which may occur with overdose include dyspnoea and ventricular pauses (see section 4.8).
Med drugimi klinično pomembnimi neželenimi učinki, ki se lahko pojavijo v primeru prevelikega odmerjanja, so dispneja in prekatne pavze (glejte poglavje 4.8).
Other moderate CYP3A4 inhibitors (e.g. amprenavir, aprepitant, erythromycin and fluconazole) would be expected to have a similar effect and can as well be co-administered with Possia.
Pričakovati je mogoče, da drugi zmerni zaviralci CYP3A4 (npr. amprenavir, aprepitant, eritromicin in flukonazol) vplivajo podobno in se jih prav tako lahko uporablja hkrati z zdravilom Possia.
Possia reduces the chances of you having another heart attack or a stroke or of dying from a disease related to your heart or blood vessels.
Zdravilo Possia zmanjša možnost ponovnega srčnega infarkta, možganske kapi ali smrti zaradi bolezni, povezane s srcem ali ožiljem.
Patients with asthma/COPD may have an increased absolute risk of experiencing dyspnoea with Possia (see section 4.8).
Bolniki z astmo/KOPB imajo med uporabo zdravila Possia večje absolutno tveganje dispneje (glejte poglavje 4.8).
Patients treated with clopidogrel can be directly switched to Possia if needed (see section 5.1).
Če je treba, lahko bolniki, zdravljeni s klopidogrelom, neposredno preidejo na zdravilo Possia (glejte poglavje 5.1).
• Hypersensitivity to the active substance or to any of the excipients listed in section 6.1 (see
• Preobčutljivost za zdravilno učinkovino ali katerokoli pomožno snov našteto v poglavju 6.1 (glejte poglavje 4.8).
Possia reduced the occurrence of the primary composite endpoint compared to clopidogrel in both the UA/NSTEMI and STEMI population (Table 3).
Zdravilo Possia je zmanjšalo pojavljanje primarne sestavljene končne točke v primerjavi s klopidogrelom tako v populaciji z nestabilno angino pektoris/NSTEMI kot s STEMI (preglednica 3).
The Cmax and AUC of the active metabolite were reduced by 89% and 56%, respectively.
Cmax aktivnega presnovka se je zmanjšala za 89 % in njegova AUC za 56 %.
• standard blisters (with sun/moon symbols) in cartons of 60 and 180 tablets
• standardni pretisni omoti (s simboloma sonce/mesec) v škatlah s 60 in 180 tabletami.
In PLATO study, patients on ticagrelor had a higher risk of hyperuricaemia than those patients receiving clopidogrel (see section 4.8).
V študiji PLATO je bilo tveganje hiperurikemije večje med zdravljenjem s tikagrelorjem kot med zdravljenjem s klopidogrelom (glejte poglavje 4.8).
PERFORATED UNIT DOSE BLISTER (100X1 TABLETS)
PERFORIRANI PRETISNI OMOTI ZA ENKRATNI ODMEREK (100 x 1 TABLETA)
Other concomitant therapy
Druga sočasna zdravila
If the association cannot be avoided, their concomitant use should be made with caution (see section 4.5).
Če se hkratni uporabi ni mogoče izogniti, mora biti sočasno zdravljenje previdno (glejte poglavje 4.5).
Creatinine levels may increase during treatment with Possia (see section 4.8).
Med zdravljenjem z zdravilom Possia se koncentracija kreatinina lahko poveča (glejte poglavje 4.8).
TIMI Minor Bleed: Clinically apparent with 30-50 g/l decrease in haemoglobin.
Blaga krvavitev po TIMI: Klinično opazna z znižanjem hemoglobina 30-50 g/l.
Co-administration of ticagrelor with potent CYP3A inducers may decrease exposure and efficacy of ticagrelor (see section 4.4).
Sočasna uporaba tikagrelorja z močnimi induktorji CYP3A lahko zmanjša izpostavljenost tikagrelorju in njegovo učinkovitost (glejte poglavje
What Possia is and what it is used for What you need to know before you take Possia
Kaj je zdravilo Possia in za kaj ga uporabljamo Kaj morate vedeti, preden boste vzeli zdravilo Possia Kako jemati zdravilo Possia Možni neželeni učinki
It is not recommended to use Possia if you are pregnant or may become pregnant.
Zdravila Possia ni priporočljivo uporabljati, če ste noseči ali bi lahko zanosili.
Cmax and AUC for ticagrelor were 12% and 23% higher in patients with mild hepatic impairment compared to matched healthy subjects, respectively (see section 4.2).
Pri bolnikih z blago okvaro jeter je bila Cmax 12 % večja in AUC 23 % večja kot pri usklajenih zdravih preiskovancih (glejte poglavje 4.2).
TIMI Major Bleed: Clinically apparent with >50 g/l decrease in haemoglobin or intracranial haemorrhage.
Huda krvavitev po TIMI: Klinično opazna z znižanjem hemoglobina > 50 g/l ali intrakranialna krvavitev.
Possia does not affect tests of
Zdravilo Possia ne vpliva na teste delovanja pljuč.
- Keep this leaflet.
• Navodilo shranite.
Due to reports of cutaneous bleeding abnormalities with SSRIs (e.g., paroxetine, sertraline and citalopram), caution is advised when administering SSRIs with Possia as this may increase the risk of
Zaradi poročil o kožnih krvavitvenih motnjah med uporabo selektivnih zaviralcev prevzema serotonina, (npr. paroksetina, sertralina in citaloprama) je pri sočasni uporabi selektivnih zaviralcev serotonina in zdravila Possia potrebna previdnost, ker lahko poveča tveganje krvavitev.
The concomitant use of Possia with doses of simvastatin or lovastatin greater than 40 mg is not recommended (see section 4.4).
Sočasna uporaba zdravila Possia z odmerki simvastatina ali lovastatina, večjimi od 40 mg, ni priporočljiva (glejte poglavje 4.4).
In the presence of digoxin, the Cmax and AUC of ticagrelor and its active metabolite were not affected.
Cmax in AUC tikagrelorja in njegovega aktivnega presnovka se v prisotnosti digoksina nista spremenili.
The concomitant use of Possia with doses of simvastatin or lovastatin greater than 40 mg is not recommended (see section 4.5).
Sočasna uporaba zdravila Possia z odmerki simvastatina ali lovastatina, večjimi od 40 mg, ni priporočljiva (glejte poglavje 4.5).
Tablet core: mannitol (E421), dibasic calcium phosphate, sodium starch glycolate, hydroxypropyl-cellulose (E463), magnesium stearate (E470b)
Jedro manitol (E421) kalcijev hidrogenfosfat magnezijev stearat (E470b) natrijev karboksimetilškrob hidroksipropil-celuloza (E463)
• other medicines such as ketoconazole (used to treat fungal infections), clarithromycin (used to treat bacterial infections), nefazodone, (an antidepressant), ritonavir and atazanavir (used to treat HIV infection and AIDS), cisapride (used to treat heartburn), ergot alkaloids (used to treat migraines and headaches).
• druga zdravila, npr. ketokonazol (uporablja se za zdravljenje glivičnih okužb), klaritromicin (uporablja se za zdravljenje bakterijskih okužb), nefazodon (antidepresiv), ritonavir in atazanavir (uporabljata se za zdravljenje okužbe s HIV in aidsa), cisaprid (uporablja se za zdravljenje zgage), alkaloidi ergot (uporabljajo se za zdravljenje migrene in glavobolov).
Due to observations of mostly asymptomatic ventricular pauses and bradycardia, caution should be exercised when administering Possia concomitantly with medicinal products known to induce bradycardia (see section 4.4).
Zdravila, za katera je znano, da povzročajo bradikardijo Zaradi pojavljanja ventrikularnih pavz in bradikardije, ki so večinoma asimptomatske, je previdnost potrebna pri uporabi zdravila Possia sočasno z zdravili, za katera je znano, da povzročajo bradikardijo (glejte poglavje 4.4).
Ticagrelor is primarily a CYP3A4 substrate and a mild inhibitor of CYP3A4.
Tikagrelor je v prvi vrsti substrat CYP3A4 in blago zavira CYP3A4.
Your doctor may want you to stop taking Possia 7
Zdravnik vam bo morda naročil, da 7 dni pred operacijo nehate jemati zdravilo Possia.
However, due to potential pharmacodynamic interactions, caution should be exercised with the concomitant administration of Possia with medicinal products known to alter haemostasis (see section 4.4).
Toda zaradi možnih farmakodinamičnih medsebojnih delovanj je med sočasno uporabo zdravila Possia in zdravil, ki vplivajo na hemostazo, potrebna previdnost (glejte poglavje 4.4).
Exposure to ticagrelor and the active metabolite were approximately 20% lower in patients with severe renal impairment (creatinine clearance <30 ml/min) compared to subjects with normal renal function
Izpostavljenost tikagrelorju in njegovemu aktivnemu presnovku je bila pri bolnikih s hudo okvaro ledvic (očistek kreatinina < 30 ml/min) približno 20 % manjša kot pri osebah z normalnim delovanjem ledvic (glejte poglavje 4.2).
Higher exposures to ticagrelor (approximately 25% for both Cmax and AUC) and the active metabolite were observed in elderly (≥ 75years) ACS patients compared to younger patients by the population pharmacokinetic analysis.
Pri starejših osebah (≥ 75 let) z ACS so v primerjavi z mlajšimi s populacijsko farmakokinetično analizo ugotovili večjo izpostavljenost tikagrelorju (približno 25 % za Cmax in AUC) in njegovemu aktivnemu presnovku.
• calendar blisters (with sun/moon symbols) in cartons of 14, 56 and 168 tablets
• koledarski pretisni omoti (s simboloma sonce/mesec) v škatlah po 14, 56 in 168 tablet.
Other strong inhibitors of CYP3A4 (clarithromycin, nefazodone, ritonavir, and atazanavir) would be expected to have similar effects and their concomitant use with Possia is contraindicated (see section 4.3 and 4.4).
Pričakovati je mogoče, da drugi močni zaviralci CYP3A4 (klaritromicin, nefazadon, ritonavir ali atanazavir) vplivajo podobno, zato je njihova sočasna uporaba z zdravilom Possia kontraindicirana (glejte poglavji 4.3 in 4.4).
Your doctor will tell you how much to take (usually between
Zdravnik vam bo povedal, koliko zdravila morate jemati (po navadi med 75 in 150 mg na dan).
If clinically indicated, medicinal products that alter haemostasis should be used with caution in combination with Possia (see section 4.4).
Če so klinično indicirana zdravila, ki vplivajo na hemostazo, jih je treba v kombinaciji z zdravilom Possia uporabljati previdno (glejte poglavje 4.4).
• PVC-PVDC/Al perforated unit dose transparent blister of 10 tablets; cartons of 100x1 tablets (10 blisters).
• Prosojen perforiran pretisni omot za enkratni odmerek iz PVC-PVDC/Al z 10 tabletami; škatle s 100x1 tableto (10 pretisnih omotov) .
For Possia, 0.9% of patients discontinued study drug because of dyspnoea compared with 0.1% taking clopidogrel.
Zaradi dispneje je zdravljenje z raziskovanim zdravilom prekinilo 0,9 % bolnikov, zdravljenje s klopidogrelom pa 0,1 % bolnikov.
This reduces the chance of a blood clot forming that can
Tako se zmanjša verjetnost nastanka krvnega strdka, ki lahko zmanjša pretok krvi.
A. MANUFACTURER(S) RESPONSIBLE FOR BATCH
A. IZDELOVALCI, ODGOVORNI ZA SPROŠČANJE SERIJ
• Feeling or being sick
• omotica ali vrtoglavica
Most reported symptoms of dyspnoea were mild to moderate in intensity, and most were reported as a single episode
Večina opisanih simptomov z dispnejo je bila blagih do zmernih, in večina jih je bila zabeleženih kot enkraten pojav zgodaj po začetku zdravljenja.
Respiratory, thoracic and mediastinal disorders e, Haemorrhoidal
Bolezni dihal, prsnega koša in mediastinalnega prostora dispnejac, epistaksa
Bleeding of many different kinds can be increased, for example:
Opredelitve kategorij krvavitev:
• PVC-PVDC/Al transparent blister (with sun/moon symbols) of 10 tablets; cartons of 60 tablets (6 blisters) and 180 tablets (18 blisters).
• Prosojen pretisni omot (s simboloma sonce/mesec) iz PVC-PVDC/Al z 10 tabletami; škatle s 60 tabletami (6 pretisnih omotov) in s 180 tabletami (18 pretisnih omotov).
Switching data
Podatki o prehodu
No dose adjustment is necessary for patients with renal impairment (see section 5.2).
Bolnikom z okvaro ledvic odmerka ni treba prilagoditi (glejte poglavje 5.2).
Possia and clopidogrel did not differ in rates of PLATO Major Fatal/Life-threatening bleeding, PLATO total Major bleeding, TIMI Major bleeding, or TIMI Minor bleeding (Table 2).
Zdravilo Possia in klopidogrel se nista razlikovala po deležih hudih krvavitev s smrtnim izidom/smrtno nevarnih krvavitvah po PLATO, vseh hudih krvavitev po PLATO, hudih krvavitev po TIMI in blagih krvavitev po TIMI (preglednica 2).
- recent surgery (including dental work) - you have a condition that affects blood clotting - recent bleeding from your stomach or gut (such as a stomach ulcer or colon ‘polyps')
• če imate večje tveganje krvavitev zaradi: - nedavne resne poškodbe - nedavne operacije (vključno z zobozdravstvenimi posegi) - če imate kakšno motnjo strjevanja krvi - nedavne krvavitve v želodcu ali črevesu (npr. iz razjede na želodcu ali "polipov" v debelem
- If you get any side effects, talk to your doctor or pharmacist.
• Če opazite kateri koli neželeni učinek, se posvetujte s svojim zdravnikom ali s farmacevtom.
Therefore, appropriate clinical and/or laboratory monitoring is recommended when giving narrow therapeutic index P-gp dependent medicinal products like digoxin or cyclosporin concomitantly with Possia (see section 4.4).
Zato je med sočasno uporabo zdravila Possia in zdravil, ki so odvisna od P-gp in imajo ozek terapevtski indeks (kakršno je digoksin ali ciklosporin), priporočljiv ustrezen klinični in/ali laboratorijski nadzor (glejte poglavje 4.4).
The hyperuricaemia AEs reported were 0.5% for ticagrelor vs. 0.2% for clopidogrel.
Neželeni učinki hiperurikemije so bili opisani pri 0,5 % s tikagrelorjem in pri 0,2 % s klopidogrelom.
Each film coated tablet contains 90 mg ticagrelor.
Ena filmsko obložena tableta vsebuje 90 mg tikagrelorja.
6.6 Special precautions for disposal
6.6 Posebni varnostni ukrepi za odstranjevanje in ravnanje z zdravilom
(95% CI)
RRRa (%) (95 % IZ)
Uncommon (affects 1 to 10 users in 1,000)
Občasni (pojavijo se pri 1 do 10 od 1000 bolnikov)
Co-administration of Possia and CYP3A4 substrates with narrow therapeutic indices (i.e., cisapride and ergot alkaloids) is not recommended, as ticagrelor may increase the exposure to these medicinal products (see section 4.5).
Sočasna uporaba zdravila Possia in substratov CYP3A4 z ozkim terapevtskim indeksom (tj. cisaprida in alkaloidov ergot) ni priporočljiva, ker lahko tikagrelor poveča izpostavljenost tem zdravilom (glejte poglavje 4.5).
In patients with stable coronary artery disease on ASA, ticagrelor demonstrates a rapid onset of pharmacological effect as demonstrated by a mean Inhibition of Platelet Aggregation (IPA) for ticagrelor at 0.5 hours after 180 mg loading dose of about 41%, with the maximum IPA effect of 89% by 2-4 hours post dose, and maintained between 2-8 hours.
To se kaže s povprečno 41 % zavrtjem agregacije trombocitov (IPAInhibition of Patelet Aggregation) 0,5 ure po 180-mg polnilnem odmerku tikagrelorja in največjim učinkom IPA 89 % v 2 do 4 urah po odmerku in se ohrani od 2 do 8 ur.
• selective serotonin reuptake inhibitors (abbreviated as SSRIs) taken as antidepressants such as paroxetine, sertraline and citalopram
• selektivne zaviralce prevzema serotonina (s kratico: SSRI), ki se uporabljajo kot antidepresivi,
Co-administration of Possia and CYP3A4 substrates with narrow therapeutic indices (i.e., cisapride or ergot alkaloids) is not recommended, as ticagrelor may increase the exposure to these medicinal products (see section 4.4).
Sočasna uporaba zdravila Possia in substratov CYP3A4 z ozkim terapevtskim indeksom (tj. cisaprida ali alkaloidov ergot) ni priporočljiva, ker tikagrelor lahko poveča izpostavljenost tem zdravilom (glejte poglavje 4.4).
• Rash
• srbenje
Detailed information on this medicinal product is available on the website of the European Medicines
DATUM ZADNJE REVIZIJE BESEDILA Podrobne informacije o zdravilu so objavljene na spletni strani Evropske agencije za zdravila (EMA) http://www.ema.europa.eu
- bleeding after surgery or from cuts and wounds that is more than normal (common) - bleeding from your stomach lining (ulcer) (uncommon).
- krvavitev po operaciji ali krvavitev iz ureznin ali ran, ki je močnejša kot po navadi (pogosto) - krvavitev iz želodčne sluznice (razjede) (občasno) - krvavitev iz dlesni (občasno) - kri v ušesu (redko) - notranja krvavitev (redko) - krvavitev v sklepe, ki povzroči bolečo oteklino (redko).
What Possia looks like and contents of the pack Film-coated tablet (tablet): The tablets are round, biconvex, yellow, film-coated marked with a “90”
Filmsko obložena tableta (tableta): Tablete so okrogle, na obeh straneh izbočene, rumene filmsko obložene tablete z oznako "90" nad "T" na eni strani.
Mean serum uric acid concentration increased approximately 15% with ticagrelor compared to approximately 7.5% with clopidogrel and after treatment was stopped, decreased to approximately 7% on ticagrelor but with no decrease observed for clopidogrel.
Povprečna koncentracija sečne kisline v serumu se je s tikagrelorjem povečala za približno 15 % in s klopidogrelom za približno 7,5 %.
SRI = serious recurrent ischaemia; RI = recurrent ischaemia; TIA = transient ischaemic attack; ATE = arterial thrombotic event.
Negativno RRR pomeni povečanje relativnega tveganja izključujoč nemi miokardni infarkt RPI = resna ponovna ishemija, PI = ponovna ishemija, TIA = tranzitorna ishemična ataka, ATD = arterijski trombotični dogodek.
Due to observations of mostly asymptomatic ventricular pauses in an earlier clinical study, patients with an increased risk of bradycardic events (e.g. patients without a pacemaker who have sick sinus syndrome, 2nd or 3rd degree AV block or bradycardic-related syncope) were excluded from the main PLATO study evaluating the safety and efficacy of Possia.
V glavno PLATO študijo varnosti in učinkovitosti zdravila Possia niso bili vključeni bolniki s tveganjem bradikardnih dogodkov (npr. bolniki brez srčnega spodbujevalnika in z boleznijo sinusnega vozla, AV-blokom 2. ali 3. stopnje ali sinkopo zaradi bradikardije).
However, more PLATO combined Major + Minor bleeding occurred with ticagrelor compared with clopidogrel.
Med uporabo tikagrelorja pa se je pojavilo več hudih + blagih krvavitev po PLATO kot med uporabo klopidogrela.
Possia 90 mg film-coated tablets ticagrelor
Possia 90 mg filmsko obložene tablete tikagrelor
No data are available on concomitant use of Possia with potent P-gp inhibitors (e.g. verapamil, quinidine, cyclosporin) that may increase ticagrelor exposure.
Podatkov o sočasni uporabi zdravila Possia z močnimi zaviralci P-gp (npr. z verapamilom, kinidinom, ciklosporinom), ki lahko povečajo izpostavljenost tikagrelorju, ni.
Keep this medicine out of the reach and sight of children.
Zdravilo shranjujte nedosegljivo otrokom!
No dose adjustment is necessary for patients with mild hepatic impairment.
Bolnikom z blago okvaro jeter odmerka ni treba prilagoditi.
Co-administration of Possia with strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin, nefazodone, ritonavir, and atazanavir) is contraindicated (see section 4.3 and 4.5).
Sočasna uporaba zdravila Possia z močnimi zaviralci CYP3A4 (npr. s ketokonazolom, klaritromicinom, nefazodonom, ritonavirjem in atazanavirjem) je kontraindicirana (glejte poglavji 4.3 in 4.5).
Co-administration of ticagrelor with strong CYP3A4 inducers (e.g. rifampicin, dexamethasone, phenytoin, carbamazepine and phenobarbital) is discouraged, as co-administration may lead to a decrease in exposure and efficacy of ticagrelor (see section 4.5).
Tikagrelorja ni priporočljivo uporabljati sočasno z močnimi induktorji CYP3A4 (npr. rifampicinom, deksametazonom, fenitoinom, karbamazepinom in fenobarbitalom), ker lahko sočasna uporaba zmanjša izpostavljenost tikagrelorju in njegovo učinkovitost (glejte poglavje 4.5).
Renal function should be checked after one month and thereafter according to routine medical practice, paying special attention to patients ≥ 75 years, patients with moderate/severe renal impairment and those receiving concomitant treatment with an ARB.
Posebno pozornost je treba nameniti bolnikom, starim ≥ 75 let, bolnikom z zmerno/hudo okvaro ledvic in tistim, ki sočasno prejemajo zaviralce receptorjev angiotenzina.
Possia helps stop the clumping of platelets.
Zdravilo Possia pomaga preprečiti sprijemanje trombocitov.
Co-administration of Possia with tolbutamide resulted in no change in the plasma levels of either medicinal product, which suggest that ticagrelor is not a CYP2C9 inhibitor and unlikely to alter the CYP2C9 mediated metabolism of medicinal products like warfarin and tolbutamide.
To kaže, da tikagrelor ne zavira CYP2C9 in tako ni verjetno, da bi spremenil presnovo drugih zdravil, npr. varfarina in tolbutamida, s CYP2C9.
Taking Possia with food and drink
Jemanje zdravila Possia skupaj s hrano in pijačo Zdravilo Possia lahko vzamete s hrano ali brez nje.
During the Holter substudy in PLATO, more patients had ventricular pauses >3 seconds with ticagrelor than with clopidogrel during the acute phase of their ACS.
V holterski podštudiji PLATO je imelo med akutno fazo ACS ventrikularne pavze, ≥3 sekund, več bolnikov, ki so dobivali tikagrelor, kot bolnikov, ki so dobivali klopidogrel.
• You are taking any of the following medicines: ketoconazole (used to treat fungal infections), clarithromycin (used to treat bacterial infections), nefazodone (an antidepressant), ritonavir and atazanavir (used to treat HIV infection and AIDS).
klaritromicin (uporablja se za zdravljenje bakterijskih okužb), nefazodon (antidepresiv), ritonavir in atazanavir (uporabljata se za zdravljenje okužbe s HIV in aidsa).
The increase in ventricular pauses in the acute phase of ACS was more pronounced in ticagrelor patients with history of CHF (9.2% versus 5.4% in patients without CHF history; for clopidogrel patients, 4.0% in those with versus 3.6% in those without CHF history) This imbalance did not occur at one month: 2.0% versus 2.1% for ticagrelor patients with and without CHF history respectively; and 3.8% versus 1.4% with clopidogrel.
Porast ventrikularnih pavz v akutni fazi ACS je bil izrazitejši pri bolnikih, ki so dobivali tikagrelor in so imeli anamnezo kongestivnega srčnega popuščanja (9,2 % v primerjavi s 5,4 % med bolniki brez takšne anamneze; pri bolnikih, ki so dobivali klopidogrel, 4,0 % pri tistih z anamnezo kongestivnega srčnega popuščanja in 3,6 % pri tistih brez takšne anamneze.